936 results on '"Fujimura, Yoshihiro"'
Search Results
2. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023
3. COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm
4. Quantification of the contribution of individual coagulation factors to haemostasis using a microchip flow chamber system and reconstituted blood from deficient plasma.
5. A novel haemodilution chip mounted on the total thrombus‐formation analysis system, a flow chamber system, enables stable analysis of platelet products under low platelet concentration/high shear conditions
6. Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura
7. Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome
8. Blood group antigen A on von Willebrand factor is more protective against ADAMTS13 cleavage than antigens B and H
9. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
10. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
11. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
12. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
13. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
14. Mutations and Common Polymorphisms in ADAMTS13 Gene Responsible for von Willebrand Factor-Cleaving Protease Activity
15. Hereditary Deficiency of ADAMTS13 Activity: Upshaw–Schulman Syndrome
16. The number of CD34+CD133+ hematopoietic stem cells residing in umbilical cord blood (UCB) units is not correlated with the numbers of total nucleated cells and CD34+ cells: a possible new indicator for quality evaluation of UCB units
17. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome
18. Stealth thrombosis of brain and kidney in a girl with Upshaw–Schulman syndrome not receiving prophylactic plasma infusions
19. A novel quantitative method to evaluate the contribution of platelet products to white thrombus formation in reconstituted blood under flow conditions
20. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan
21. Thrombotic Microangiopathy
22. Clinical guides for atypical hemolytic uremic syndrome in Japan
23. Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy
24. No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome
25. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan
26. Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency
27. Correction: Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis
28. Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension
29. New load transfer structure to reduce body deformation in side collisions.
30. Identification of epitopes on ADAMTS13 recognized by a panel of monoclonal antibodies with functional or non-functional effects on catalytic activity
31. Correction to: Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome
32. Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis
33. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
34. Congratulatory speech—The road to TMA analysis in Japan with Professor Miyata’s group—
35. A historical review on VWF-heparin binding domain, implicating the roles in angiogenesis and complement activation
36. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation
37. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the Japanese society of nephrology and the Japan pediatric society
38. Anti‐Kg antibodies induce monocyte phagocytosis of the red blood cells
39. Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin
40. A rapid, fully automated and highly sensitive ADAMTS13 gold particle immunoassay using a routine biochemistry analyser
41. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma
42. Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B
43. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy
44. Decreased ADAMTS13 Levels in Patients after Living Donor Liver Transplantation
45. Two newborn-onset patients of Upshaw–Schulman syndrome with distinct subsequent clinical courses
46. A second national questionnaire survey of TMA
47. Pivotal role of ADAMTS13 function in liver diseases
48. National questionnaire survey of TMA
49. Response to ‘Death during pregnancy: Thrombotic thrombocytopenic purpura or septic shock?’
50. Case of maternal and fetal deaths due to severe congenital thrombotic thrombocytopenic purpura (Upshaw–Schulman syndrome) during pregnancy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.